Key facts
- Lucida Medical’s last known valuation is $44.7M (Mar 2026).
- It has raised $23.6M; the latest was Later Stage VC ($11.6M) in Mar 2026.
- Notable investors include Innovate UK, Creative Destruction Lab, The FSE Group, Cambridge Enterprise Ventures, XTX Ventures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Lucida Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Lucida Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lucida Medical
Developer of an artificial intelligence-based healthcare technology designed to assist clinicians in detecting and diagnosing cancer. The company's technology develops imaging and multi-omics biomarkers and reporting tools using artificial intelligence and MRI to support cancer screening and diagnosis, enabling clinicians and physicians to make cancer detection accurate, accessible, cost-effective, and quick.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 24
- Website
- lucidamedical.com/
- Ownership
- Privately Held (backing)
Lucida Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lucida Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lucida Medical in its N-PORT filings yet. We sweep new filings monthly.